Register entry
GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
- Registered sites
- 0
- Drug products
- 0
- Live patents
- 25
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
25Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Jun 2027 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Dec 2027 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Feb 2029 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Aug 2029 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Mar 2030 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Sept 2030 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Oct 2030 |
| BREO ELLIPTA | FLUTICASONE FUROATE; VILANTEROL TRIFENATATE | Apr 2031 |
| INCRUSE ELLIPTA | UMECLIDINIUM BROMIDE | Dec 2027 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.